Lundbeck

The impact of brain disorders is escalating. It is estimated that brain disorders directly affect half the world’s population, and the effects are felt throughout society. Every day we go to work to address high unmet medical needs for people living with brain disorders. Patients who have few or no treatments available. Through cutting-edge science and strong partnerships, we develop and market some of the world’s leading treatments, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. Our most important contribution is easing the burden of the millions of people living with brain disorders. Whether it is migraine, depression, or other brain disorders, patients, their carers, and society as a whole depend on us. At Lundbeck, we are - Advancing brain health. Transforming lives. #AdvancingBrainHealth #FocusedInnovator

-For U.S. audiences only- Recently, Lundbeck US and Otsuka Pharmaceutical Companies (U.S.) joined forces with Barbara Corcoran to raise awareness about agitation in Alzheimer’s dementia through the ‘I Wish I Knew’ campaign. In New York City, Barbara passionately shared why this cause is so close to her heart, including her experience caring for her mother, who showed signs of agitation in Alzheimer’s dementia. Learn more about the campaign in this PEOPLE Magazine | PEOPLE.com piece: https://bit.ly/4gNT5W6.

Exciting Visit from the American Ambassador to Denmark! ✈️ Last week, we were honored to welcome the American Ambassador to Denmark, Alan M. Leventhal, to our headquarters for an insightful meeting and an exclusive tour of our research labs. The discussions centered around innovation in neuroscience, continuous improvements in our understanding of the brain and Lundbeck’s commitment to advancing brain health. The Ambassador’s visit provided an opportunity to also showcase some of the latest brain research and how our dedicated team bring this forward. A special highlight was the tour of our research labs, where the Ambassador got a firsthand look at the innovative technologies and methodologies we employ to push the boundaries of neuroscience 🧠 We are inspired by the Ambassador’s enthusiasm to the field of neuroscience. Thank you, Alan M. Leventhal, for visiting us. Charl van Zyl, Johan Luthman, Tarek Samad #AdvancingBrainHealth #InnovationInNeuroscience

#BrainHealth is key to overall health and wellbeing - let’s not leave it behind 🧠 The global burden and impact of brain disorders is growing. It is estimated that brain disorders directly affect half the world’s population, and their consequences are felt throughout society. At Lundbeck, as we rapidly improve our understanding of the biology of the brain, we also hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. We’re beginning to leverage artificial intelligence and advanced technologies to access the brain, enabling us to develop treatment opportunities that were previously unimaginable. Dr. Morten Grunnet, Vice President and Head of Neuroscience at Lundbeck shared his thoughts on the importance of brain research with the European Brain Council as part of their ‘No Health Without Brain Health’ campaign at the European Parliament. In the video below, he discusses the challenges and opportunities in European brain research and innovation, and the importance of maintaining a competitive environment. 👇

Did you know that it takes approximately 10-15 years to develop a new medicine, from the initial idea to an approved treatment available to patients? At Lundbeck, we are proud to have ~1,000 dedicated employees in R&D, working tirelessly to advance brain health. In a rapidly evolving field of science, we continuously adapt new ways of working and improve efficiency to shift resources towards innovation. With a growing understanding of the biology of the brain, we hold ourselves accountable for exploring new opportunities for treatments. We call this being a Focused Innovator. #AdvancingBrainHealth #Neuroscience #BrainHealth #FocusedInnovator

World Mental Health Day 2024 at Lundbeck: An impressive global effort 🌍 Lundbeck marked World Mental Health Day 2024 with a series of impactful initiatives across the globe. Our efforts included discussions on the state of psychiatry as well as illuminating historic monuments to raise awareness. We hosted press conferences featuring international experts and engaged employees in meaningful activities, such as creating murals that reflect the duality of mental health conditions. We organized special events focused on workplace mental health and participated in community activities like street races and wellness walks. Our teams also engaged in 'plogging' to promote environmental and mental health, and ran radio campaigns to spread awareness. Art exhibitions and public murals were created to unite against stigma, while seminars and talks provided insights into stress management and mental illness. We collaborated with local communities and patient associations to amplify our message, using multi-channel media approaches to reach a wider audience. These initiatives not only highlighted the importance of mental health but also demonstrated our ongoing commitment to eliminating stigma and promoting mental well-being across the world. Thank you to all our partners and affiliates for your dedication and support. Together, we stay committed to our purpose: Advancing brain health. Transforming lives. 💚

The Lundbeck Capital Markets Event is in full swing at our Valby headquarters where professional investors, analysts, and journalists have gathered to explore how we’re delivering on our Focused Innovator strategy. Presentations are highlighting Lundbeck’s strategic roadmap, focusing on leveraging our deep expertise, strategic partnerships, and innovation capabilities to deliver value for patients, society, and shareholders. This aligns with our commitment to making a meaningful difference by addressing high unmet needs for people living with brain disorders, and the event provides insights into how we’re advancing our R&D portfolio for conditions like migraine, PTSD, epilepsies, MSA, and other neurological diseases. We’re now aiming to have four new molecular entities (NMEs) in phase III by 2026. We’re also discussing how the proposed acquisition of Longboard Pharmaceuticals supports our long-term sustainable growth ambitions by adding a late-stage asset in the epilepsy space. Our guests will have the opportunity to explore this and other subjects in Q&A sessions with Lundbeck’s top management before being treated to a tour of our cutting-edge R&D facilities. Our dedication to advancing brain health by curiously exploring new opportunities for treatments underpins our role as a Focused Innovator. The brain health challenge is real – let’s solve it together. #CapitalMarketsEvent #FocusedInnovator #AdvancingBrainHealth

Hoje, 18 de outubro, celebramos o Dia do Médico. É um dia dedicado àqueles que, mesmo enfrentando desafios diários, estão sempre empenhados em fazer a diferença na vida de seus pacientes. Parabéns pelo compromisso em transformar vidas! A Lundbeck, que tem profundo respeito por esses profissionais, parabeniza os médicos pelo incansável propósito de cuidar. Que a sua dedicação continue sendo uma fonte de esperança e cura para tantos! #diadomedico

Did you know that the World Health Organization lists depression as the leading cause of disability worldwide? Depression is one of Lundbeck’s focus disease areas and is a serious medical condition that is associated with a series of symptoms including melancholy, loss of energy as well as suicidal thoughts. Depression can affect all aspects of life, including relationships with family, friends and community. The staggering number of people affected highlights the urgent need for awareness and support. At Lundbeck, we are committed to easing the burden of brain disorders, including depression, rooted in our strong legacy within psychiatry. #AdvancingBrainHealth #Depression #DiseaseAwareness

At Lundbeck, we are committed to advancing understanding and treatment options for migraine, and we believe in the importance of open dialogue to support those affected. We recently had the privilege of interviewing Prof. Dawn C. Buse, a leading expert in migraine research. In our conversation, she passionately discusses her mission to destigmatize migraine, a condition that many endure in silence. In the interview, Prof. Buse highlights the significant burden migraine places on patients' daily lives, revealing the often-overlooked co-morbidities and personal costs associated with this debilitating disease. Join us in raising awareness and breaking the stigma surrounding migraine! #MigraineAwareness #AdvancingBrainHealth